Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Medicine Research    2017, Vol. 1 Issue (2) : 35     DOI: 10.21127/yaoyimr20170010
Minireview |
Activities of Naturally Occurring Alkaloids Bulleyaconitine A
Shiyang Zhaia,Wenjing Zhoua,Yifan Xua,Xiaosu Wanga,Xiao Yea,Shuyue Wanga,Wenhui Wua,Ruihua Guoabcde*
a College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China
b Shanghai Engineering Research Center of Aquatic-Product Processing & Preservation, Shanghai 201306, China
c National Experimental Teaching Demonstration Center for Food Science and Engineering (Shanghai Ocean University), Shanghai 201306, China
d Laboratory of Quality and Safety Risk Assessment for Aquatic Product on Storage and Preservation (Shanghai), Ministry of Agriculture, Shanghai 201306, China
e Quality Supervision, Inspection and Testing Center for Cold Storage and Refrigeration Equipment, Ministry of Agriculture, Shanghai 201306, China
Download: PDF(300 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks     Supporting Info

Bulleyaconitine A, a C19-diterpenoid alkaloid extracted from Aconitum bulleyanum Diels, showed various bioactivities, including anti-inflammatory, antinociceptivity, immunomodulatory effects as well as some toxicities. This paper reviewed the bioactivities of Bulleyaconitine A and the relevant mechanisms, toxicities, as well as the metabolism.

Keywords bulleyaconitine A      antinociceptivity      anti-inflammatory      immunomodulatory effects      toxicities     
Corresponding Authors: Shiyang Zhai,Wenjing Zhou,Ruihua Guo   
Issue Date: 07 December 2017
E-mail this article
E-mail Alert
Articles by authors
Shiyang Zhai
Wenjing Zhou
Yifan Xu
Xiaosu Wang
Xiao Ye
Shuyue Wang
Wenhui Wu
Ruihua Guo
Cite this article:   
Shiyang Zhai,Wenjing Zhou,Yifan Xu, et al. Activities of Naturally Occurring Alkaloids Bulleyaconitine A[J]. Medicine Research, 2017, 1(2): 3537.
Figure 1  The structure of bulleyaconitine A.
Figure 2  The structures metabolites of bulleyaconitine A.
Metabolites R R1 R2 R4 R5 R6 R7 R8 Enzymes
M1 -C2H5 -OMe -H -C2H5O -OAc -H -OH -OMe CYP3A, 2C, 2D, 2E1
M2 -C2H5 -OH -H -C2H5O -OAc -H -OH -OMe Transformed by M1 or M3
M3 -C2H5 -OH -H -C2H5O -OAc -H -OMe -OMe CYP3A, 2C, 2E1
M4 -C2H5 -OMe -H -C2H5O -OH -H -OMe -OMe CYP3A, 2C, 2D, 2E1
M5 -C2H5 -OMe -H -H -OAc -H -OMe -OMe CYP3A, 2C
M6 -C2H5 -OMe Δ2,3 -C2H5O -OAc -H -OMe -OMe CYP3A, 2C
M7 -C2H5 -OMe -OH -C2H5O -OAc -H -OMe -OMe CYP3A, 2C, 2D
M8 -C2H5 -OMe -H -C2H5O -OAc Δ15,16 Δ15,16 -OMe CYP3A, 2C
M9 -C2H5 -OMe -H -C2H5O -OAc -OH -OMe -OMe CYP3A, 2C, 2D
M10 -C2H5 -OMe -H -C2H5O -OAc -H -OMe - CYP3A,2C
M11 -C2H5 -OMe -H -C2H5O -OAc -H -OMe -OMe CYP3A, 2C, 1A2, 2E1
M12 - -OMe -H -C2H5O Δ8,15 Δ8,15 -OMe -OMe CYP3A, 2C, 2D, 2E1
Table 1  The structures metabolites of bulleyaconitine A
1 Yang X. L.; Yang D. N.; Yang Q. R.; Zhu K.; Zhang Y. S. World Clin. Drugs 2013, 34, 80.2 Wang C. F.; Gerner P.; Schmidt B.; Xu Z. Z.; Nau C.; Wang S. Y.; Ji R. R.; Wang G. K. Anesth. Analg.2008, 107, 1397.3 Wang C. F.; Gerner P.; Wang S. Y.; Wang G. K. Anesthesiology 2007, 107, 82.4 Weng W. Y.; Xu H. N.; Huang J. M.; Wang G. Q.; Shen T.; Zhang J. F. Biol. Pharm. Bull.2005, 28, 747.5 Tang X, CH. Chin. J. New Drugs Clin. Rem.1986, 5, 120.6 Bi Y. F.; Zhuang X. Y.; Zhu H. B.; Song F. R; Liu Z. Q.; Liu S. Y. Biomed. Chromatogr.2015, 29, 1027.7 Weng W. Y. Master’s Thesis, Transdermal Characteristic and Transdermal Delivery System of Bulleyaconitine A, Fudan University, Shanghai, 2003, p. 3.8 Xiao R. L. , Master’s Thesis The Study of Drug Delivery for Bulleyaconitine A-Multivesicular Liposome and Bulleyaconitine A-DSPE-PEG2000 Micelle, Shenyang Pharmaceutical University, Shenyang, 2008, p. 4.9 Wu X. H. Master’s Thesis, The Study on Microemulsion of Bulleyaconitine A and Its Waterborne Substrate Transdermal Drug Delivery System, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 2006, p. 8.10 Duan S. F.; Shi J. F. J. Pharm. Pract.2013, 31, 217.11 Li T. F.; Wu H. Y.; Wang Y. R.; Li X. Y.; Wang Y. X. Sci. Rep.2017, 7, 112 Zhang X.; Zhou B.; Lu H. L. Chron. Pathematol. J.2016, 17, 1210.13 Li T. F.; Fan H.; Wang Y. X. J. Pain 2016, 17, 530.14 Chen, X Y.; Xia X. L.; Xiong J. M.; Tai P. R. Yunnan J. Tradit. Chin. Med. Mater. Medica 1996, 7, 54.15 Wang Z. S.; Zhang X. P. J. Pain 1995, 3, 120.16 Zheng X. H. Clin. Med.2005, 25, 65.17 Pan G. X.; Du D. P. Shanghai Med. J.2013, 36, 523.18 Xiao W.; Lin D. D. Clin. J. Chin. Med. 2015, 7, 1.19 Du N.; Zhu D. Y. J. Henan Univ. (Med. Sci.) 2015, 34, 50.20 Long L.; Zhao J. X.; Jia R. L.; Liu Y. Y.; Han L.; Li Z. G. Clin. Medication J.2013, 11, 16.21 Lu Y.; Han L.; Li H.; Weng W. Y. Chin. J. New Drug Clin. Rem.2007, 26, 755.22 Yang C. H. Med. Pharm. Yunnan 1995, 16, 75.23 Bello-Ramírez A. M.; Nava-Ocampo A. A. Fund. Clin. Pharmacol.2004, 18, 699.24 Li T. F.; Gong N.; Wang Y. X. Front. Pharmacol.2016, 7, 1.25 Weng W. Y.; Xu H. N.; Huang J. M.; Wang, G Q.; Shen T.; Zhang J. F. J. Chromatogr. B 2005, 816, 315.26 Xiong X.; Zhai S. D.; Yao Z. Q. Biosci. Biotechnol. Biochem.2009, 73, 1527.27 Wang Q.; Tan B.; Gong Y. J.; Ji G. X.; Zhang Y.; Yang P.; Li W.; Shen T. J. Pharm. Biomed. Anal.2012, 71, 202.
[1] Liangyan Liu, Chang-An Geng. Phytochemical and Biological Progress of Cynanchum paniculatum[J]. Medicine Research, 2019, 3(1): 190200.
Full text



Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States